Medtronic’s announcement to spin off its diabetes business into a separate, publicly traded company surprised many. After all, diabetes is one of the fastest-growing global health challenges, and the technology supporting it — from smart insulin pumps to continuous glucose monitors — is advancing rapidly.But as the dust settles, the logic becomes clear: focus, operational alignment, and long-term value creation. And now that Medtronic is clearly open to reshaping its portfolio, one has to ask: Could the spine division be next?
Lessons from the Diabetes Spin-Off
The diabetes unit has long operated under a different rhythm than the rest of Medtronic. While the company’s core strengths lie in hospital-based, high-margin therapies like cardiovascular and surgical robotics, diabetes is consumer-facing, requiring distinct go-to-market strategies, support models, and innovation cycles.
Despite past regulatory challenges — including a 2021 FDA warning letter — the diabetes division has rebounded strongly, posting five consecutive quarters of double-digit growth. Spinning it off now allows Medtronic to unlock its potential while improving overall financial performance.
From a shareholder perspective, the move is also attractive. The spin-off is expected to boost Medtronic’s gross margin by 50 basis points and operating margin by 100, while enhancing adjusted earnings per share. For the newly formed company, it’s a chance to pursue partnerships, strategies, and innovations tailored to the dynamic and growing diabetes market.
In other words, the move wasn’t about retreat — it was about precision.
Where Spine Fits in the Bigger Picture?
The spine division is a different kind of business, yet some of the strategic rationale behind the diabetes decision could also apply here.Medtronic’s spine segment, built around technologies like spinal implants, navigation systems, biologics, and robotics (e.g., Mazor X), operates in an intensely competitive market. It faces rivals like the recently merged Globus Medical-NuVasive — battling for market share in a space where pricing pressure is high and differentiation is becoming difficult.Moreover, innovation in spine tends to be incremental, not transformative. This makes it harder to command premium margins, especially compared to other Medtronic units like Structural Heart or Neurovascular.
Why a Spine Spin-Off Could Make Strategic Sense?
- Operational Focus: Like diabetes, the spine has its own commercial rhythm. A standalone spine company could move faster, make targeted investments, and pursue niche acquisitions, unencumbered by broader corporate priorities.
- Financial Optimization: Spinning off the spine could improve Medtronic’s margin profile, freeing capital and management bandwidth for faster-growing, higher-margin areas.
- Unlocking Value: A focused spine player could attract investors specifically looking for exposure to orthopedic and robotic surgery segments.
- Autonomous Growth Strategy: Freed from Medtronic’s broader roadmap, a spine-focused firm could accelerate innovation, adopt new business models, and tailor its go-to-market approach in a more agile way.
Why It Might Not Happen?— At Least Not Yet
Despite the rationale, a spine spin-off isn’t an obvious next step, and there are reasons Medtronic might keep it in-house:
- Robotics Integration: The spine business is tightly linked to Medtronic’s robotic platform and navigation technologies, which the company views as core to its digital surgery strategy.
- Interdependency with Neuroscience: Spine overlaps significantly with neuromodulation and other therapies housed under Medtronic’s neuroscience umbrella. Untangling them operationally could be messy.
- No Immediate Pressure: Unlike diabetes, where a distinct consumer model and past regulatory issues added urgency, spine hasn’t emerged as a drag on performance or investor sentiment.
###